1,411 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
A $20 Billion Sweet Spot in Biotech https://www.fool.com/investing/2019/12/28/a-20-billion-sweet-spot-in-biotech.aspx?source=iedfolrf0000001 Dec 28, 2019 - Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.
3 Rare Disease Drug Launches to Watch in 2020 https://www.fool.com/investing/2019/12/27/4-rare-disease-drug-launches-to-watch-in-2020.aspx?source=iedfolrf0000001 Dec 27, 2019 - Patients who inherit life-threatening blood disorders have some important new treatment options.
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-685884 Dec 24, 2019 - Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
3 Top European Dividend Stocks for U.S. Investors https://www.fool.com/investing/2019/12/23/3-top-european-dividend-stocks-for-us-investors.aspx?source=iedfolrf0000001 Dec 23, 2019 - These companies offer strong growth potential and good dividends for investors prepared to look further afield for profit.
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs http://www.zacks.com/stock/news/679924/pharma-stock-roundup-lillys-upbeat-2020-outlook-fda-nod-for-pfe-mrks-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-679924 Dec 20, 2019 - Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU http://www.zacks.com/stock/news/678331/abbvies-jak-inhibitor-rinvoq-receives-approval-for-ra-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-678331 Dec 19, 2019 - AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.
Novartis' Asthma Candidate Fails in LUSTER Phase III Studies http://www.zacks.com/stock/news/675066/novartis-asthma-candidate-fails-in-luster-phase-iii-studies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-675066 Dec 17, 2019 - Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.
Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu http://www.zacks.com/stock/news/672976/novartis-gets-positive-chmp-opinion-for-wet-amd-drug-beovu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-672976 Dec 16, 2019 - Novartis (NVS) obtains positive CHMP opinion for its wet AMD drug Beovu. A potential approval will boost its ophthalmology franchise.
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America http://www.zacks.com/stock/news/667191/the-zacks-analyst-blog-highlights-novartis-abbvie-sanofi-pioneer-natural-resources-and-aqua-america?cid=CS-ZC-FT-press_releases-667191 Dec 12, 2019 - The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy http://www.zacks.com/stock/news/667105/gilead-teams-up-with-kiniksa-submits-bla-for-car-t-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-667105 Dec 12, 2019 - Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.

Pages: 12345678...142

<<<Page 3>